Karin Lykke-Hartmann
CEO and founder
Notify Therapeutics
Notify Therapeutics develops a first-in-class, non-hormonal treatment targeting initial ovarian follicle development in the hormone-independent phase. This therapy is designed for infertile women who are unresponsive to standard hormone treatments for low ovarian reserve. The approach aims to generate quality eggs while controlling for risks associated with multiple pregnancies.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$7MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Many women with low ovarian reserves do not respond to standard hormone therapies for infertility, leaving them with limited options for achieving pregnancy. Current treatments often fail to address the initial stages of follicle development, which are critical for successful egg production.
Solution
Notify Therapeutics is developing a first-in-class, non-hormonal treatment designed to improve fertility outcomes for women with low ovarian reserves who are unresponsive or low-responding to standard hormone therapies. The therapy targets the hormone-independent phase of initial ovarian follicle development, aiming to enhance the production of high-quality eggs. Preclinical studies have demonstrated proof-of-concept efficacy, suggesting the potential to overcome the limitations of existing hormonal treatments. The non-hormonal approach also minimizes the risks associated with multiple pregnancies, offering a safer alternative for women seeking fertility assistance. Preliminary toxicology studies have shown no safety concerns.
Target Audience
The primary target audience includes women with low ovarian reserves who are unresponsive or low-responding to standard hormone therapies, as well as fertility clinics and reproductive endocrinologists seeking alternative treatment options.
Features
- Non-hormonal formulation targeting the initial, hormone-independent phase of ovarian follicle development.
- Demonstrated proof-of-concept efficacy in rodent models and ex-vivo studies utilizing patient samples.
- Designed to improve egg quality in women with low ovarian reserves.
- Aims to provide a treatment option for women unresponsive or low-responding to standard hormone therapies.
- Reduced risk of multiple pregnancies compared to hormone-based treatments.